Junction: Cholangiocarcinoma

Novel Therapeutic Strategy Could Improve Chemotherapy Response in CCA

Findings in a murine model of cholangiocarcinoma (CCA) showed that PXS-5505 might be a useful component in combination therapy. The results of the study were recently presented at The Liver Meeting 2021, hosted by the American Association for the Study of Liver Diseases (AASLD). PXS-5505, an oral drug that was developed by Pharmaxis, inhibits all…

ASPH May Be Involved in Cholangiocarcinoma Chemoresistance

Aspartate beta-hydroxylase (ASPH) may be involved in chemoresistance in cholangiocarcinoma, according to a new study presented in a poster at the 2021 annual meeting of the American Association for the Study of Liver Diseases. ASPH is a 2-oxoglutarate (2-OG)-dependent enzyme that is highly expressed in cholangiocarcinoma. “Increased 2-OG antagonizes chemotherapeutic effect in cholangiocarcinoma progression,” the…

Alagille Syndrome

Liver Organoids Present New Opportunities in Medical Research

When conducting medical research into organ-specific diseases, scientists often have to either retrospectively or prospectively recruit patients with the relevant medical conditions. However, all modern clinical trials must be approved by an ethics board, and some trials are simply deemed too risky to be conducted on human subjects.  In addition, any tests done on human…

Newly Developed Multiplex Network Could Improve Rare Disease Research

Researchers in Austria developed a multiplex network by mapping genes and their interactions on multiple levels, which can help better identify genetic defects and study their consequences.  To build the network, the team led by Jörg Menche, PhD, adjunct principal investigator at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences…

Potential Cholangiocarcinoma Treatment Receives FDA’s Fast Track Designation

The US Food and Drug Administration (FDA) granted TT-00420, a potential new treatment for cholangiocarcinoma, Fast Track Designation, as announced in a press release by TransThera Sciences (Nanjing) Inc., the developers of the treatment. Currently, the only potentially curative treatment option for cholangiocarcinoma is surgery. However, some patients are not eligible for surgery.  Read more…

Stereotactic Ablative Radiotherapy as a Promising Cholangiocarcinoma Treatment

Stereotactic ablative radiotherapy is a promising and noninvasive treatment option for patients with nonresectable cholangiocarcinoma, according to a new Danish study published in Acta Oncologica. The approach has the added benefits of offering a short treatment time and having acceptable toxicity.  “[Stereotactic ablative radiotherapy] should be considered for fragile patients not suited for standard chemotherapy…

Multiple Biomarkers May Predict Survival in Patients With Cholangiocarcinoma

Tumor differentiation, location, and first-line chemotherapy responses are more predictive of progression-free survival (PFS) rate than gene mutations for patients with unresectable cholangiocarcinoma (CC), according to the results of a retrospective study published online in Alternative Therapies in Health and Medicine. Gene mutations also did not significantly influence treatment response, the authors said. One favorable…

Next post in CC Insights